Astrasana Holding AG is pleased to announce the successful completion of the majority acquisition of Releaf for Pets, marking a significant milestone for Europe’s foremost approved CBD veterinary product line.
Founded in 2019, Releaf for Pets has already successfully obtained state approvals for multiple products. These products are registered for distribution across Europe and are currently available in retail chains in Czech Republic, Austria, and Bulgaria.
Professor Tomas Ryska, Founder and CEO of Releaf for Pets, underscores the immense medical potential of CBD in animal products, stating: “The effectiveness of CBD in animals is remarkably high, particularly in dogs, which exhibit a response up to 20 times stronger to the plant-based compound. The challenge has been the absence of fully approved products in this domain, and Releaf for Pets is now closing that gap.”
Yves Antoniazzi, CEO of Astrasana Holding AG, expresses enthusiasm about the new partnership, stating, “In the past 10-20 years, there has been a significant humanisation of pets. For many pet owners, their animals mean almost as much as themselves. Those familiar with the cannabis market understand the general challenges of approved products and the complications of usage instructions. Releaf for Pets fits perfectly into the corporate portfolio of the Astrasana Holding Group.”
Astrasana Holding AG is an internationally operating company with branches in Switzerland, Czech Republic, the United Kingdom, and Japan. In addition to its activities in the pharmaceutical cannabis sector, the company also trades in legal cannabinoid products.
